MPP5/PALS1 Polyclonal Antibody, ALEXA FLUOR® 350 Conjugated

Applications

  • WB
  • IF(IHC-P)
  • IF(IHC-F)
  • IF(ICC)

Predicted Reactivity

  • Human
  • Mouse
  • Rat
  • Dog
  • Cow
  • Sheep
  • Pig
  • Horse
  • Chicken
  • Rabbit
Overview
Catalog # bs-11887R-A350
Product Name MPP5/PALS1 Polyclonal Antibody, ALEXA FLUOR® 350 Conjugated
Applications WB, IF(IHC-P), IF(IHC-F), IF(ICC)
Predicted Reactivity Human, Mouse, Rat, Dog, Cow, Sheep, Pig, Horse, Chicken, Rabbit
Specifications
Conjugation ALEXA FLUOR® 350
Host Rabbit
Source KLH conjugated synthetic peptide derived from human MPP5/PALS1
Immunogen Range 201-300/675
Clonality Polyclonal
Isotype IgG
Concentration 1ug/ul
Purification Purified by Protein A.
Storage Buffer Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Storage Condition Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
Target
Subcellular location Cytoplasm, Cell membrane
Synonyms FLJ12615; MAGUK p55 subfamily member 5; Membrane protein palmitoylated 5; MPP 5; MPP5; MPP5_HUMAN; PALS 1; PALS1; Protein associated with Lin-7; Stardust Drosophila; Stardust.
Background Two highly conserved complexes are responsible for the assembly of tight junctions, the Crumbs-Pals1-Patj complex and the Cdc42-Par6-Par3-aPKC complex. Tight junctions assist in the formation of polarity in the epithelia by establishing a barrier to separate apical and basolateral membranes. Pals1, importantly, mediates interaction between the two complexes via interaction with Par6. Loss of Pals1 function results in delayed polarization, decreased transepithelial electrical resistance and an inability to form lumenal cysts. Because tumors exhibit perturbations in epithelial polarity, Pals1 presents a new potential target in the study of carcinogenesis.
Application Dilution
WB 1:300-5000
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200